Combination of β-cryptoxanthin and zinc has potent effects on apoptotic cell death and suppression of bone resorption-related gene expression in osteoclastic cells

International Journal of Molecular Medicine

Volumn 22, Issue 2, 2008, Pages 221-228

  Yamaguchi, Masayoshi ^a,b   Uchiyama, Satoshi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cryptoxanthin; Apoptosis; Gene expression; Osteoclastogenesis; Zinc

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA CRYPTOXANTHIN; CASPASE 3; CASPASE 3 INHIBITOR; CATHEPSIN K; COLONY STIMULATING FACTOR 1; CYCLOHEXIMIDE; DNA FRAGMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; ZINC;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL COUNT; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENRICHMENT CULTURE; FEMALE; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ACID PHOSPHATASE; ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BONE RESORPTION; CASPASE 3; CATHEPSINS; CYCLOHEXIMIDE; DNA FRAGMENTATION; FEMALE; GENE EXPRESSION; HUMANS; ISOENZYMES; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; NF-KAPPA B; OSTEOCLASTS; PROTEIN SYNTHESIS INHIBITORS; RANK LIGAND; XANTHOPHYLLS; ZINC;

EID: 48749120742     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm_00000012     Document Type: Article

References (37)

1. Bonjour J-P, Schurch M-A and Rozzori R: Nutritional aspects of hip fractures. Bone 18: 1395-1445, 1996.
2. Yamaguchi M: Isoflavone and bone metabolism: Its cellular mechanism and preventive role in bone loss. J Health Sci 48: 209-222, 2002.
3. Yamaguchi M and Uchiyama S: Effect of carotenoid on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro: The unique anabolic effect of β-cryptoxanthin. Biol Pharm Bull 26: 1188-1191, 2003.
4. Yamaguchi M and Uchiyama S: β-Cryptoxanthin stimulates bone formation and inhibits bone resorption in tissue culture in vitro. Mol Cell Biochem 258: 137-144, 2004.
5. Uchiyama S and Yamaguchi M: β-Cryptoxanthin stimulates cell proliferation and transcriptional activity in osteoblastic MC3T3-E1 cells. Int J Mol Med 15: 675-681, 2005.
6. Uchiyama S and Yamaguchi M: β-Cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells. J Cell Biochem 95: 1224-1234, 2005.
7. Uchiyama S and Yamaguchi M: Inhibitory effect of β-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol 67: 1297-1305, 2004.
8. Uchiyama S and Yamaguchi M: β-Cryptoxanthin stimulates apoptotic cell death and suppresses cell function in osteoclastic cells: Change in their related gene expression. J Cell Biochem 98: 1185-1195, 2006.
9. Uchiyama S and Yamaguchi M: Oral administration of β-cryptoxanthin prevents bone loss in ovariectomized rats. Int J Mol Med 17: 15-20, 2006.
10. Prasad AS, Halsted JA and Nadimi M: Syndrome of iron deficiency anemia, hepatosplenomegaly, hydroganadism, dwarfism and geophagia. Am J Med 31: 532-547, 1961.
11. Burt RE, Kahn HK and Sullivan JF: Newer aspects of the roles of zinc, manganese, and copper in human nutrition. Clin Chem 21: 501-520, 1975.
12. Hsieh HS and Navia JM: Zinc deficiency and bone formation in guinea pig alveolar implants. J Nutr 110: 1582-1588, 1980.
13. Oner G, Bhaumick B and Bala RM: Effect of zinc deficiency on serum somatomedin levels and skeletal growth in young rats. Endocrinology 114: 1860-1863, 1984.
14. Yamaguchi M, Oishi H and Suketa Y: Stimulatory effect of zinc on bone formation in tissue culture. Biochem Pharmacol 36: 4007-4012, 1987.
15. Hashizume M and Yamaguchi M: Stimulatory effect of β-alanyl-L-histidinato zinc on cell proliferation is dependent on protein synthesis in osteoblastic MC3T3-E1 cells. Mel Cell Biochem 122: 59-64, 1991.
16. Yamaguchi M, Segawa Y, Shimokawa N, Tsuzuike N and Tagashira E: Inhibitory effect of β-alanyl-L-histidinato zinc on bone resorption in tissue culture. Pharmacology 45: 292-300, 1992.
17. Kishi S and Yamaguchi M: Inhibitory effect of zinc compounds on osteoclast-like cell formation in mouse marrow culture. Biochem Pharmacol 48: 1225-1230, 1994.
18. Holloway WR, Collier FM, Herbst RE, Modge JM and Nicholson GC: Osteoblast-mediated effects of zinc on isolated rat osteoclasts: Inhibition of bone resorption and enhancement of osteoclast number. Bone 19: 137-142, 1996.
19. Yamaguchi M: Role of zinc in bone formation and bone resorption. J Trace Elem Exp Med 11: 119-135, 1998.
20. Reginster JY, Strause LG, Saltman P and Franchimont P: Trace elements and postmemopausal osteoporosis. A preliminary study of decreased serum manganese. Med Sci Res 16: 337-338, 1998.
21. Herzberg M, Foldes J, Steinberg R and Menczel J: Zinc excretion in osteoporotic women. J Bone Miner Res 5: 251-257, 1990.
22. Kishi S, Segawa Y and Yamaguchi Y: Histomorphological confirmation of the preventive effect of β-ananyl-L-histidinato zinc on bone loss in ovariectomized rats. Biol Pharm Bull 17: 862-865, 1994.
23. Uchiyama S, Ihiyama K, Hashimoto K and Yamaguchi M: Synergistic effect of β-cryptoxanthin and zinc sulfate on the bone component in rat femoral tissues in vitro: The unique anabolic effect with zinc. Biol Pharm Bull 28: 2142-2145, 2005.
24. Yamaguchi M, Uchiyama S, Ishiyama K and Hashimoto K: Oral administration in combination with zinc enhances β-cryptoxanthin-induced anabolic effects on bone components in the femoral tissues of rats in vivo. Biol Pharm Bull 29: 371-374, 2006.
25. Ogasawara T, Katagiri M, Yamamoto A, Hoshi K, Takato T, Nakamura K, Tanaka S, Okayama H and Kawaguchi H: Osteoclast differentiation by RANKL requires NF-κB-mediated down regulation of cyclin-dependent kinase 6 (cdk6). J Bone Miner Res 19: 1128-1136, 2004.
26. Burstone MS: Histochemical demonstrations of acid phosphatase with naphthol AS-phosphate. J Natl Cancer Inst 221: 523-539, 1958.
27. Minkin C: Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34: 285-290, 1982.
28. Preaux A-M, D'Oratho M-P, Bralet M-P, Laperche Y and Mavier P: Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 36: 615-622, 2002.
29. Ceriotti G: Determination of nucleic acids in animal tissues. J Biol Chem 214: 59-70, 1955.
30. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
31. Juan TS, McNiece IK, Jenkins NA, Gilbert DJ, Copeland NG and Fletcher FA: Molecular characterization of mouse and rat CPP32 beta gene encoding a cysteine protease resembling interleukin-1 beta converting enzyme and CED-3. Oncogene 13: 749-755, 1996.
32. Cassady AI, King AG, Cross NC and Hume DA: Isolation and characterization of the genes encoding mouse and human type-5 acid phosphatase. Gene 130: 201-207, 1993.
33. Rantakokko J, Aro HT, Savontaus M and Vuorio E: Mouse cathepsin K: cDNA cloning and predominant expression of the gene in osteoclasts, and in some hypertrophying chondrocytes during mouse development. FEBS Lett 393: 307-313, 1996.
34. Li X, Ho SN, Luna J, Giacalone J, Thomas DJ, Timmerman LA, Crabtree GR and Francke U: Cloning and chromosomal localization of the human and murine genes for the T-cell transcription factors NFATc and NFATp. Cytogenet Cell Genet 68: 185-191, 1995.
35. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP and Baltimore D: Cloning of the p50 DNA binding subunit of NF-kappa B: Homology to red and dorsal. Cell 62: 1019-1029, 1990.
36. Zaidi M, Blair HC, Moonga BS, Abe E and Huang CL: Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Mine Res 18: 599-609, 2003.
37. Asagiri M and Takayanagi H: The molecular understanding of osteoclast differentiation. Bone 40: 251-264, 2007.